IMNM Stock Overview A biotechnology company, develops targeted cancer therapies. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Immunome, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Immunome Historical stock prices Current Share Price US$11.08 52 Week High US$30.96 52 Week Low US$8.15 Beta 1.84 1 Month Change 18.00% 3 Month Change -26.08% 1 Year Change 32.54% 3 Year Change -32.85% 5 Year Change n/a Change since IPO -17.62%
Recent News & Updates
Immunome: A Recently Acquired Lead Asset And A Small Market Dec 11
New minor risk - Share price stability Nov 27
President recently bought US$962k worth of stock Nov 26
Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 14
Immunome Presents Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021 Oct 30
Immunome, Inc. Appoints Roee Shahar as Executive Vice President, Commercial Oct 08 See more updates
Immunome: A Recently Acquired Lead Asset And A Small Market Dec 11
New minor risk - Share price stability Nov 27
President recently bought US$962k worth of stock Nov 26
Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 14
Immunome Presents Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021 Oct 30
Immunome, Inc. Appoints Roee Shahar as Executive Vice President, Commercial Oct 08
Executive VP of Operations notifies of intention to sell stock Sep 22
Immunome, Inc. to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors At the European Society for Medical Oncology Congress 2024 Sep 13
Consensus revenue estimates increase by 21%, EPS downgraded Aug 19
Price target decreased by 8.7% to US$30.60 Aug 13
Immunome, Inc. Appoints Phil Tsai as Chief Technical Officer Jun 27
President recently bought US$1.4m worth of stock May 22
Consensus EPS estimates fall by 97%, revenue upgraded May 21
Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Substantially all Assets of Atreca, Inc. (NasdaqGS:BCEL). May 21
Immunome, Inc. Announces Promotion of Max Rosett to Chief Financial Officer May 18 Immunome, Inc. has filed a Follow-on Equity Offering in the amount of $200 million. May 15
Immunome, Inc. Appoints Kinney Horn as Chief Business Officer May 03
Immunome, Inc., Annual General Meeting, Jun 12, 2024 Apr 28
Immunome, Inc. Appoints Sandra M. Swain to Board of Directors Apr 26
Consensus EPS estimates fall by 17% Apr 04
Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Assets from Ayala Pharmaceuticals, Inc. (OTCPK:ADXS). Mar 27 Immunome, Inc. has completed a Follow-on Equity Offering in the amount of $200 million. Feb 15
Immunome, Inc. has completed a Follow-on Equity Offering in the amount of $200 million.
New minor risk - Share price stability Feb 07
Immunome, Inc. Announces Promotion of Max Rosett to Executive Vice President, Operations Feb 01
Consensus EPS estimates upgraded to US$0.97 loss Jan 29
Immunome: Why It Has Doubled Over The Last Month Jan 18
Immunome Appoints Phil Roberts as Chief Technical Officer Jan 05
Immunome, Inc. Announces Board Changes Jan 02
Immunome, Inc. Announces Executive Changes, Effective January 2, 2024 Dec 30 Immunome, Inc. announced that it has received $124.722508 million in funding from Enavate Sciences, EcoR1 Capital, LLC, Redmile Group, LLC, Janus Henderson Group plc, Avidity Partners Management, L.P., Woodline Partners LP and other investors
Immunome, Inc. Appoints Jean-Jacques Bienaimé to Board of Directors Nov 09
Immunome Appoints Bob Lechleider as Chief Medical Officer Oct 20
Less than half of directors are independent Oct 13
New major risk - Shareholder dilution Oct 05
Immunome, Inc. (NasdaqCM:IMNM) entered into an agreement to acquire MorphImmune, Inc. from Research Bridge Partners, Investment Arm and others for $51.7 million. Jul 01 Immunome, Inc. announced that it expects to receive $124.722508 million in funding Jun 30
No longer forecast to breakeven Mar 20
Will Immunome (NASDAQ:IMNM) Spend Its Cash Wisely? Mar 17
Immunome, Inc. Announces Formation of Antibody-Drug Conjugate and T Cell Redirection Advisory Board Feb 09
Is Immunome (NASDAQ:IMNM) In A Good Position To Deliver On Growth Plans? Nov 20
Price target decreased to US$8.50 Nov 16
High number of new directors Nov 16
Immunome Presents Preclinical Data on Novel Anti-EPN1 Antibody IMM20059 at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting Nov 08
Forecast to breakeven in 2024 Sep 27
Immunome Announces Publication in Clinical & Translational Immunology Highlighting B Cell Repertoires in Patients with Breast Cancer Aug 24
Immunome GAAP EPS of -$0.74 Aug 05
Here's Why We're Watching Immunome's (NASDAQ:IMNM) Cash Burn Situation Aug 05
Immunome, Inc.’S Covid-19 Cocktail Retains Neutralizing Activity Against the Most Prevalent Omicron Subvariants in the Us, Ba.4/5 and Ba.2.12.1 Jul 07
Immunome gains 34% after preclinical data on COVID-19 antibody Jun 30
Immunome, Inc. Announces Initiation of Phase 1b Study of IMM-BCP-01 for the Treatment of COVID-19 Jun 10
Immunome, Inc. Provides Research & Development Update on Lead Oncology Candidate Targeting IL-38 May 24
Immunome, Inc. Announces Data Demonstrating COVID-19 Antibody Cocktail Potently Clears Omicron BA.1 Variant in Hamster Model and Retains Activity Against BA.2 Subvariant May 20
Immunome, Inc., Annual General Meeting, Jun 15, 2022 May 02
High number of new and inexperienced directors Apr 27
Price target increased to US$33.00 Feb 23
We Think Immunome (NASDAQ:IMNM) Can Afford To Drive Business Growth Feb 21
Immunome, Inc. Antibody Cocktail Effective Against SARS-CoV-2 Omicron Variant in Vitro Live Virus Testing Feb 10
Immunome Provides Update on Investigational New Drug Application for IMM-BCP-01 for the Treatment of COVID-19 Jan 12
Immunome, Inc. Expects IMM-BCP-01 Antibody Cocktail to Neutralize the SARS-CoV-2 Omicron Variant Dec 03
Immunome Announces Submission of Investigational New Drug (IND) Application for IMM-BCP-01 for the Treatment of COVID-19 Nov 30
Companies Like Immunome (NASDAQ:IMNM) Are In A Position To Invest In Growth Oct 02 Immunome, Inc.(NasdaqCM:IMNM) dropped from Russell 3000E Growth Index
Director recently bought US$248k worth of stock May 29 Immunome SARS-CoV-2 Antibody Cocktail Neutralizes UK, South Africa, Brazil and California Variants in Preclinical Testing; Progressing Towards IND Filing
Immunome launches $27M private placement Apr 26
Do Institutions Own Immunome, Inc. (NASDAQ:IMNM) Shares? Mar 12
Immunome, Inc. Discovers Antibodies Capable of Neutralizing Multiple SARS-CoV-2 Variants, Including the South African Variant, in Pseudovirus Testing Feb 19
New 90-day high: US$39.01 Feb 19
Abzena Selects Immunome, Inc.’s Partner Research Organization for IMM-BCP-01 Feb 04
New 90-day high: US$20.24 Feb 03
Read This Before Selling Immunome, Inc. (NASDAQ:IMNM) Shares Jan 18
New 90-day high: US$13.73 Jan 17 Shareholder Returns IMNM US Biotechs US Market 7D -15.2% -6.5% -4.0% 1Y 32.5% 1.3% 24.0%
See full shareholder returns
Return vs Market: IMNM exceeded the US Market which returned 24% over the past year.
Price Volatility Is IMNM's price volatile compared to industry and market? IMNM volatility IMNM Average Weekly Movement 10.9% Biotechs Industry Average Movement 10.7% Market Average Movement 6.4% 10% most volatile stocks in US Market 16.8% 10% least volatile stocks in US Market 3.2%
Stable Share Price: IMNM's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: IMNM's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company’s clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Show more Immunome, Inc. Fundamentals Summary How do Immunome's earnings and revenue compare to its market cap? IMNM fundamental statistics Market cap US$693.45m Earnings (TTM ) -US$305.35m Revenue (TTM ) US$10.13m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) IMNM income statement (TTM ) Revenue US$10.13m Cost of Revenue US$91.13m Gross Profit -US$81.00m Other Expenses US$224.35m Earnings -US$305.35m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -4.89 Gross Margin -799.64% Net Profit Margin -3,014.59% Debt/Equity Ratio 0%
How did IMNM perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/19 00:14 End of Day Share Price 2024/12/19 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Immunome, Inc. is covered by 9 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Lut Ming Cheng Cantor Fitzgerald & Co. Michael Schmidt Guggenheim Securities, LLC Lut Ming Cheng J.P. Morgan
Show 6 more analysts 
